CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.

Autor: Gutierrez JA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC. Electronic address: antonio.gutierrez@duke.edu., Heizer GM; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC., Rockhold FW; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Mahaffey KW; Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA., Fowkes FGR; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK., Berger JS; Departments of Medicine and Surgery, New York University School of Medicine, New York, NY., Baumgartner I; Swiss Cardiovascular Centre, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Held P; University of Gothenburg, Sweden., Katona BG; AstraZeneca Gaithersburg, Gaithersburg, MD., Norgren L; Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Blomster JI; Turku University Hospital, Turku, Finland., Hiatt WR; University of Colorado School of Medicine and CPC Clinical Research, Aurora, CO., Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC.
Jazyk: angličtina
Zdroj: American heart journal [Am Heart J] 2020 Nov; Vol. 229, pp. 118-120. Date of Electronic Publication: 2020 Aug 16.
DOI: 10.1016/j.ahj.2020.07.017
Databáze: MEDLINE